Daridorexant and Digoxin (Digoxin Sandoz 0.25 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
P-glycoprotein inhibition may increase exposure to a narrow-therapeutic-index substrate.
Clinical significance and safety
Daridorexant may increase exposure to digoxin, the active ingredient in Digoxin, through P-glycoprotein inhibition. The label advises caution with narrow-therapeutic-index P-gp substrates. A prescriber should assess whether monitoring or a treatment change is needed; toxicity is not inevitable in every patient.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.